Clonazepam

Limits on what this shows

• Key negative findings: In the Mohamed et al rat study, therapeutic-dose and abuse-dose clonazepam given alone were not reported to significantly reduce complex I, II, III, or IV activity; a significant decrease in complexes I, III, and IV was seen only with tramadol (therapeutic and abuse dose) and with the tramadol-clonazepam abuse-dose combination, at doses exceeding the maximum recommended human daily dose.
• At-risk subgroups: None established for humans; the cardiomyocyte finding raises a theoretical question for patients with pre-existing cardiac mitochondrial vulnerability, not established in this review.
• Counter-evidence on record: See key negative findings: therapeutic-dose clonazepam alone did not impair brain ETC complexes in the one rat study that tested it directly.

Regulatory status

Not addressed in the FDA label.

Population evidence

No human study. Ex vivo: isolated rat ventricular cardiomyocytes (Griffiths et al, 1997) showed clonazepam sustains elevated mitochondrial calcium after stimulation. In vivo animal: 70 male Wistar rats given oral therapeutic or abuse-range clonazepam, alone or with tramadol (Mohamed et al, 2013); brain electron transport chain complexes I to IV were assayed.

Mechanism

Named: inhibition of the mitochondrial Na+/Ca2+ exchanger, holding mitochondrial calcium elevated after a stimulus that would normally clear it.

Counter-evidence held on record

The cardiomyocyte finding used pharmacological tool concentrations in an isolated-cell cardiac preparation, not oral human dosing, and did not measure ATP or mitochondrial mass directly. This is not evidence that oral clonazepam impairs mitochondrial function in humans, and it is not a basis for mitochondrial-support supplementation.

Limits on what this shows

• Key negative findings: All located studies come from the same research group and the same diabetes-plus-forced-swim disease model, mostly with clonazepam combined with insulin rather than alone; no independent replication in a different lab, a different disease model, or healthy (non-diabetic) animals was found.
• At-risk subgroups: None established in humans; the model is specific to comorbid diabetes and depression in rats.
• Counter-evidence on record: This is itself a form of counter-evidence against a depletion narrative: every drug-specific oxidative-stress study located in this review reports clonazepam moving markers toward less oxidative damage, not more.

Regulatory status

Not addressed in the FDA label.

Population evidence

Male Wistar rats with streptozotocin-induced diabetes and forced-swim-test-induced depressive behavior. Wayhs et al, 2013 (liver): insulin plus clonazepam reversed elevated protein carbonyl content and restored superoxide dismutase, catalase, and glyoxalase I activity. Wayhs et al, 2014 (brain, cortex/hippocampus/striatum): insulin plus clonazepam restored total radical-trapping antioxidant potential and reduced protein carbonyl content and reactive-oxygen-species formation (DCF oxidation). da Silva Haeser et al, 2007, and Wayhs et al, 2010 (titles only, abstracts not independently retrievable this review, see Sources) describe a parallel clonazepam-specific oxidative-stress effect in the same diabetic forced-swim model.

Mechanism

Not fully named; the authors frame it as an antioxidant-restorative effect within a disease model, not a defined biochemical pathway.

Counter-evidence held on record

This is a reverse-direction, protective-appearing finding, not a depletion signal, and it must not be marketed as reassurance or as license to skip antioxidant-relevant nutrient monitoring. It comes from one lab's disease-model rats, mostly on combination therapy with insulin, and does not establish a protective effect in healthy humans on clonazepam alone.

Limits on what this shows

• Key negative findings: No human or mammalian oral-dosing study of clonazepam and copper status was located; Crossref and PubMed searches for clonazepam or benzodiazepine plus copper or trace-element terms returned no drug-specific results.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: The effect was reported for the combined carbamazepine-plus-clonazepam exposure group; the paper's brain-metal finding cannot be cleanly attributed to clonazepam alone from the data available in this review.

Regulatory status

Not addressed in the FDA label.

Population evidence

Gomes et al, 2019, Ecotoxicology and Environmental Safety 171:781-789: zebrafish (Danio rerio) exposed to environmentally relevant waterborne concentrations of carbamazepine and clonazepam, alone and combined. In brain tissue, the combined-exposure group showed decreased baseline levels of magnesium, aluminum, potassium, iron, cobalt, nickel, and copper, alongside altered glutathione S-transferase and catalase activity.

Mechanism

Not named; the paper frames this as generalized metal dyshomeostasis accompanying oxidative-enzyme disruption in exposed fish tissue, not a specific copper-handling pathway.

Counter-evidence held on record

This is an aquatic environmental-exposure model in a non-mammalian species, at waterborne concentrations meant to mimic pharmaceutical water contamination, not therapeutic oral dosing in humans. It should not be used to justify copper supplementation or avoidance in patients taking clonazepam.

Limits on what this shows

• Key negative findings: Neither study measured a functional iron marker (ferritin, transferrin saturation, hemoglobin); the gene-expression study did not isolate clonazepam's effect from escitalopram's, since both drugs were given.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: The two sources point to different endpoints (a measured brain-tissue iron decrease in an aquatic co-exposure model versus a heme-processing enzyme's gene expression increase in an oral rat combination-therapy model) and do not reinforce each other mechanistically.

Regulatory status

Not addressed in the FDA label.

Population evidence

Gomes et al, 2019 (see Copper): combined carbamazepine-plus-clonazepam waterborne exposure decreased brain iron in zebrafish, among other metals. Pałasz et al, 2026: chronic clonazepam (and escitalopram) in Sprague-Dawley rats produced region-specific changes in heme oxygenase-2 gene and protein expression (increased across multiple brain regions), assessed by immunohistochemistry and quantitative PCR, alongside region-specific changes in neuronal nitric oxide synthase and cystathionine-beta-synthase.

Mechanism

Theoretical only: heme oxygenase-2 catabolizes heme and releases iron; altered expression is a plausible but unconfirmed link to iron handling. No copper/iron transporter or absorption mechanism is named for clonazepam specifically.

Counter-evidence held on record

Gene expression is not a nutrient level, and the zebrafish finding is not an oral mammalian dosing study. Neither source supports an iron supplementation or avoidance recommendation for patients on clonazepam.

Limits on what this shows

• Key negative findings: No study, in this or any other search this review located, measured actual gut microbiome composition, diversity, or fecal community structure in an animal or human given clonazepam. Separately, a 2019 Science paper (Zimmermann et al, PMID 30733391, DOI 10.1126/science.aat9931) used a gnotobiotic mouse model and found the reverse direction operating as well: gut-bacterial genes participate in clonazepam's own metabolism (nitroreduction, glucuronidation, and enterohepatic cycling contribute to its serum metabolite profile), meaning this is a bidirectional drug-microbiome relationship, not evidence that clonazepam itself reshapes microbiome composition.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: Clonazepam is more than 98 percent hepatically metabolized with under 2 percent excreted unchanged (see Pharmacokinetic basis), which bounds how much unmetabolized drug reaches the distal gut lumen at antibacterially active concentrations after oral therapeutic dosing, a limitation the in vitro susceptibility study does not address.

Regulatory status

Not addressed in the FDA label.

Population evidence

A 2023 in vitro susceptibility study (Current Microbiology, PMID 37004588, DOI 10.1007/s00284-023-03242-y; individual author names could not be retrieved in this review due to repeated rate-limiting on the bibliographic APIs) tested clonazepam and diazepam, alone and combined with ciprofloxacin, against seven ATCC reference strains and 64 clinical isolates of the six ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp). Minimum inhibitory and minimum bactericidal concentrations were determined for clonazepam against these strains, and checkerboard/FICI testing showed a synergistic effect with ciprofloxacin against almost all tested isolates. The specific numeric MIC/MBC values for clonazepam alone, separate from diazepam's, could not be extracted from the abstract-level access available in this review.

Mechanism

Not named in the accessible abstract; the paper frames this as a drug-repositioning/repurposing candidate finding (direct antibacterial activity plus antibiotic synergy), not a defined molecular mechanism.

Counter-evidence held on record

This is in vitro susceptibility testing against isolated pathogen strains at laboratory-determined concentrations, not a whole-microbiome ecology study and not a measure of dysbiosis, diarrhea, or any GI symptom in animals or humans on clonazepam. It is not a basis for probiotic supplementation or avoidance advice.

Limits on what this shows

• Key negative findings: The related Mohamed et al 2013 rat study found no significant reduction in electron transport chain complex I to IV activity from therapeutic or abuse-dose clonazepam given alone (see Mitochondrial burden), which bounds how far the cardiomyocyte NADH finding can be generalized to whole-brain ATP output.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: ATP itself was not directly measured in either source; NADH recovery kinetics and ETC complex activity are both proxies, and they point in different directions across the two studies (impaired recovery in cardiomyocytes versus no measured complex-activity change in brain at therapeutic dose).

Regulatory status

Not addressed in the FDA label.

Population evidence

Griffiths et al, 1997, Cell Calcium 21(4):321-329: intact single rat ventricular cardiomyocytes, mitochondrial calcium measured by Indo-1 fluorescence, NADH by autofluorescence. With norepinephrine plus 3 Hz pacing, mitochondrial calcium rose to 517 plus or minus 115 nM and recovered on stimulus withdrawal; with clonazepam present, calcium rose further, to 937 plus or minus 192 nM, and remained elevated at 652 plus or minus 131 nM after the stimulus stopped, and NADH failed to recover during the washout period.

Mechanism

Named: clonazepam-mediated inhibition of the mitochondrial Na+/Ca2+ exchanger prevents calcium efflux, which in turn prevents the normal recovery of NADH, a substrate that feeds the electron transport chain.

Counter-evidence held on record

This is a single ex vivo cardiac electrophysiology study, not a measure of ATP itself, and not an oral human dosing study. It should not be read as evidence that clonazepam causes clinical fatigue or low cellular energy, and it is not a basis for any ATP-support supplement claim.

Limits on what this shows

• Key negative findings: No clonazepam-specific human study quantifying hemoglobin, hematocrit, or oxygen-carrying capacity change was located despite a direct, clean-zero-result search.
• At-risk subgroups: The listed adverse reactions were recorded in the seizure-disorder (epilepsy) indication population, which carries its own confounding factors (comorbidity, polypharmacy with other antiepileptics); this was not separated out in the label.
• Counter-evidence on record: Anemia, leukopenia, and thrombocytopenia are clinical outcomes, not measurements of iron, B12, or copper status; per this dossier's own standards, an outcome cannot be filed as a specific nutrient's deficiency without a directly measured nutrient level, which does not exist here.

Regulatory status

FDA label, Adverse Reactions section: "Hematopoietic: Anemia, leukopenia, thrombocytopenia, eosinophilia," listed among adverse experiences in seizure-disorder patients, frequency not reported. The label separately advises periodic blood counts during long-term therapy.

Population evidence

No incidence rate, denominator, or comparator group is given in the label. A direct PubMed search for clonazepam plus hemoglobin or hematocrit returned zero results.

Mechanism

Not named. StatPearls separately notes rare thrombocytopenia warranting platelet monitoring, also without a mechanism.

Counter-evidence held on record

Anemia on a bare adverse-event list is not the same as an iron, B12, or copper deficiency, and it is not evidence that clonazepam impairs oxygen delivery through a nutrient-mediated pathway. This entry exists to disclose the label listing honestly, not to suggest a supplement response.